Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify a safe dosing regimen for the combination of Torisel
and liposomal doxorubicin in patients with recurrent sarcoma. A secondary purpose of the
study is to determine how effective this combination is for the treatment of recurrent
sarcoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
National Comprehensive Cancer Network Wyeth is now a wholly owned subsidiary of Pfizer